Skip to main content

Table 1 General features of patients with dermatomyositis and health individuals

From: Relevance of serum angiogenic cytokines in adult patients with dermatomyositis

Parameters DM (n = 48) Control (n = 48) P value
Age (years) 33.3 ± 7.6 35.8 ± 8.2 1.000
White ethnicity 36 (75.0) 32 (66.7) 0.501
Female gender 36 (75.0) 36 (75.0) 1.000
Age at disease onset (years) 30.9 ± 7.4
Duration: diagnosis - symptoms (months) 5.0 (2.3–8.5)
Disease duration (years) 1 (0–4)
Clinical cumulative manifestations
 Articular involvement 14 (29.2)
 Pulmonary involvement 17 (35.4)
 Cutaneous involvement 48 (100.0)
  Gottron’s papules 47 (97.9)
  Heliotrope rash 40 (83.3)
  Facial rash 30 (62.5)
  Raynaud’ phenomenon 24 (50.0)
  “V-neck” sign 15 (31.3)
  Ulcers 10 (20.8)
  Vasculitis 10 (20.8)
  “Shawl” sign 8 (16.7)
  Calcinosis 0
MMT-8 (0–80) 78 (71–80)   
HAQ (0.00–3.00) 0.36 (0.00–2.00)
Patient VAS (0–10 mm) 5 (1–6)
Physician VAS (0–10 mm) 4 (1–5)
Creatine phosphokinase (U/L) 200 (93–960) 100 (81–161) 0.002
Aldolase (U/L) 5.9 (4.1–12.9) 3.6 (3.1–4.3) < 0.001
Lactic dehydrogenase (U/L) 412 (347–597) 323 (296–381) < 0.001
Alanine aminotransferase (U/L) 25 (16–60) 17 (13–21) < 0.001
Aspartate aminotransferase (U/L) 25 (19–52) 19 (16–22) < 0.001
Prednisone
 Current use 34 (70.8)
 Current dose (mg/day) 20.0 (3.1–50.0)
 Cumulative dosea (mg) 645 (90–2103)
 Cumulative doseb (g) 15.5 (5.8–27.8)
Immunosupressive/imunmodulatoryc   
 None 20 (41.7)
 One 11 (22.9)
 Two 17 (35.4)
  1. Results expressed as percentage (%), mean ± standard deviation, median (25th - 75th interquartile range)
  2. DM dermatomyositis, HAQ Health Assessment Questionnaire, MMT Muscle Manual Testing, VAS visual analogue score
  3. a Last 3 months; b since the begin of treatment; c imunossupressive / imunomodulatory: azathioprine (2–3 mg/kg/day), methotrexate (15–25 mg/week), cyclosporine (1.5–2.5 mg/kg/day), mycophenolate mofetil (2–3 g/day), rituximab (1 g, intravenous, at baseline and after one month - first cycle - and this schema was repeated after six months), cyclophosphamide (0.5–1.0 g/m2 body surface), leflunomide (20 mg/day) and/or intravenous human immunoglobulin (2 g/kg, daily, two consecutive days)